The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ERAS | -12.5% | N/A | N/A | -86% |
| S&P | +19.61% | +98.99% | +14.75% | +58% |
Erasca, Inc. is a clinical stage precision oncology company, It focuses on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim on July 2, 2018 and is headquartered in San Diego, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.79M | 28.5% |
| Market Cap | $359.77M | -41.3% |
| Market Cap / Employee | $3.49M | 0.0% |
| Employees | 103 | -18.3% |
| Net Income | -$33.88M | 46.4% |
| EBITDA | -$29.84M | 32.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $66.14M | -61.7% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $44.71M | -10.0% |
| Short Term Debt | $4.71M | 9.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -26.42% | 6.3% |
| Return On Invested Capital | -47.81% | -2.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$20.56M | 29.6% |
| Operating Free Cash Flow | -$20.53M | 29.6% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.65 | 1.58 | 0.92 | 0.90 | -27.24% |
| Price to Tangible Book Value | 1.65 | 1.58 | 0.92 | 0.90 | -27.24% |
| Enterprise Value to EBITDA | -13.87 | -13.29 | -3.86 | -3.64 | 0.79% |
| Return on Equity | -40.3% | -43.7% | -45.8% | -31.2% | -19.90% |
| Total Debt | $52.94M | $51.89M | $50.81M | $49.42M | -8.42% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
